A latest patient-led case sequence highlights the potential advantages of prolonged programs of Pfizer Inc’s PFE Paxlovid (nirmatrelvir / ritonavir) for people with Lengthy COVID.
The examine paperwork combined outcomes amongst 13 members, with some reporting significant symptom aid and others seeing little to no profit. The findings underscore the necessity for extra sturdy scientific analysis to judge the drug’s efficacy in managing persistent signs of the situation.
Additionally Learn: Pfizer’s Paxlovid Demonstrates Security However Raises Questions on Efficacy in Low-Danger Covid-19 Sufferers-NEJM Examine
The study concerned sufferers aged 25 to 55 who had been contaminated with SARS-CoV-2 between March 2020 and December 2022 and skilled signs comparable to fatigue, mind fog, muscle ache, irregular coronary heart charge, and post-exertional malaise.
Contributors took Paxlovid programs starting from 7.5 to 30 days, usually together with different drugs or dietary supplements, complicating the evaluation of the drug’s remoted results.
Whereas some members skilled sustained enchancment, others famous short-term aid or no change.
Two sufferers who took prolonged Paxlovid programs throughout acute reinfections reported eventual restoration to their pre-reinfection baseline. One other participant discontinued the therapy early because of extreme abdomen ache, highlighting the necessity to contemplate potential uncomfortable side effects.
The examine acknowledges its limitations, together with small, non-representative pattern dimension and reliance on self-reported knowledge, which can introduce recall or fatigue bias.
Nonetheless, its participatory method sheds mild on lived experiences that conventional medical data might overlook.
Prolonged antiviral programs have precedent in different circumstances like HIV and hepatitis C, suggesting a foundation for additional exploration in Lengthy COVID.
Researchers are inspired to analyze potential therapy pathways, together with optimum course lengths and symptom recurrence post-treatment. Bigger scientific trials are underway to systematically consider these elements.
At present, no FDA-approved therapies particularly goal Lengthy COVID. If scientific trials validate Paxlovid’s advantages, regulatory pathways like expanded entry or fast-track designation might assist make the drug out there to sufferers.
Final yr, the FDA up to date the emergency use authorization for Paxlovid.
Worth Motion: PFE inventory is up 0.49% at $26.72 throughout the premarket session eventually examine Monday.
Learn Subsequent:
Photograph through Firm
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
